A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
A phase 1/2 trial of QL2107 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients is a phase 1/2 interventional study registered as NCT06911827 by Qilu Pharmaceutical Co., Ltd., with 149 participants planned, started 2025-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: QLP2117 and QL2107.
Similar pages
not linked directly; found by shared links- TrialGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Shares QL2107, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Shares QL2107, Qilu Pharmaceutical.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.